Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases. https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Dossier - 18/04/2016 Epigenetics – heritable traits without changing the DNA sequence Epigenetics, i.e. the inheritance of traits that does not involve a change in the DNA sequence, was once a controversial subject that has since become a central focus of biological research. Epigenetic inheritance is now studied by numerous national and international research programmes. Many cellular regulatory and differentiation processes are controlled by epigenetic mechanisms that take place on different levels.https://www.gesundheitsindustrie-bw.de/en/article/dossier/epigenetics-heritable-traits-without-changing-the-dna-sequence
Dossier - 02/06/2014 Bioanalysis techniques for the characterization of biological material Science constantly provides researchers with new challenges biologists and bioanalysts have to deal with and which come from sources as varied as the ever increasing number of resistant pathogenic bacterial strains or the famine conditions in Third-World countries. In the search for scientific truths bioanalysis is the development optimization and application of the entire range of analytical methods available. However we need to keep in mind…https://www.gesundheitsindustrie-bw.de/en/article/dossier/bioanalysis-techniques-for-the-characterization-of-biological-material
Dossier - 31/03/2014 Peptides diverse molecules of life Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Peptides are gaining in importance as candidates for drugs.https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
Dossier - 02/12/2013 RNA interference confidence is returning The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
Dossier - 05/08/2013 Progress expands bioethical boundaries Bioethics is a rich and continually evolving field. In the broadest sense, bioethics relates to the way human individuals treat any form of life. The issue of whether human beings have the right to do whatever they want goes way back. Rapid progress in genetic engineering and cell biology means that it is necessary to look at certain issues in a new way and recognise that not everything that is technically feasible should actually be carried out.https://www.gesundheitsindustrie-bw.de/en/article/dossier/progress-expands-bioethical-boundaries
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable
Dossier - 05/11/2012 Cancer basic research successes and trends Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends
Dossier - 18/06/2012 Biobanks treasure chests for biomedical research The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biobanks-treasure-chests-for-biomedical-research